Literature DB >> 6286799

Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole.

J R Perfect, D T Durack.   

Abstract

Ketoconazole, amphotericin B, 5-fluorocytosine, and combinations of these drugs were compared as therapy for chronic cryptococcal meningitis in steroid-treated rabbits. Two hours after treatment of rabbits with meningitis with single drugs the mean cerebrospinal fluid concentration of 5-fluorocytosine was 4.4 microgram/ml, that of amphotericin B was less than 0.3 microgram/ml, and that of ketoconazole ranged from less than 0.2 to 0.8 microgram/ml. Serial quantitative cultures indicated that amphotericin B was the best single-drug regimen. Ketoconazole provided little or no additive effect when used in combination with fluorocytosine or therapeutic doses of amphotericin for two weeks. However, the combination of ketoconazole plus amphotericin B was at least as effective as amphotericin B plus 5-fluorocytosine over a two-week treatment regimen. The addition of ketoconazole to subtherapeutic dose of amphotericin B significantly increased the killing of cryptococci in cerebrospinal fluid.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286799     DOI: 10.1093/infdis/146.3.429

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Standardization of a hyphal inoculum of aspergilli for amphotericin B susceptibility testing.

Authors:  V Bezjak
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

3.  Effect of ketoconazole and amphotericin B on encapsulated and non-encapsulated strains of Cryptococcus neoformans.

Authors:  D Smith; H W McFadden; N G Miller
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

4.  Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein.

Authors:  M del Poeta; D L Toffaletti; T H Rude; S D Sparks; J Heitman; J R Perfect
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Anna M Schimizzi; Monia Maracci; Daniele Giannini; Flavia Carle; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  J R Perfect; D L Toffaletti; T H Rude
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

Review 8.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

9.  Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.

Authors:  J R Perfect; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

10.  In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Authors:  J R Perfect; G M Cox; R K Dodge; W A Schell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.